|
|
||||||||
J Thorac Cardiovasc Surg 2006;131:505-506
© 2006 The American Association for Thoracic Surgery
Letter to the Editor |
Paediatric Cardiac Intensive Care, The Prince Charles Hospital, Brisbane, Queensland, Australia
| The first 20% of the full text of this article appears below. |
To the Editor:
We congratulate Mackie and colleagues
1
on their randomized study on triiodothyrodine (T3) treatment in neonatal heart surgery. In their study group the authors correctly enrolled a homogenous group of infants at highest risk of postoperative low cardiac output syndrome and marked thyroid hormone suppression.
2
As already shown by several other authors, the thyroid hormone levels are suppressed after cardiopulmonary bypass (CPB), decreasing to a nadir at around 48 hours after CPB and recovering over approximately 1 week. Logically, treatment with T3 after CPB raises the T3 plasma concentrations to normal levels, and no
Related Article
J. Thorac. Cardiovasc. Surg. 2006 131: 506.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |